ライフサイエンスコーパス: intravenously

1 ntion with increasing dose (0.01-3.00 mg/kg, intravenously).

2 kg loading dose, then 6 mg/kg every 3 weeks, intravenously).

3 en MSCs are injected endotracheally (but not intravenously).

4 ay 1, followed by 100mg for Days 2-10, given intravenously).

5 nously and all subsequent doses were 2000 mg intravenously.

6 phro- and hepatotoxicities when administered intravenously.

7 ng samples from 120 rhesus macaques infected intravenously.

8 ks, and nivolumab was administered at 240 mg intravenously.

9 rapeutic dose (~18.5 GBq) of HSA (131)I-MIBG intravenously.

10 or at least 60 min every 3 weeks), all given intravenously.

11 iodinated contrast media (ICM) administered intravenously.

12 rown chronically at 5% O2, were administered intravenously.

13 very 4 weeks after cycle 4, was administered intravenously.

14 mids with Foxm1 or Foxf1 cDNAs were injected intravenously.

15 man biospecimens when delivered topically or intravenously.

16 micals and metabolite administered orally or intravenously.

17 or cells expressing high PDGFB when injected intravenously.

18 tokines compared to CAR T cells administered intravenously.

19 n improve the delivery of IVIg, administered intravenously (0.4 g/kg), to the hippocampus and reach a

20 0 mg per kilogram), or placebo, administered intravenously 14 times over a period of 52 weeks.

21 ly improved renal function when administered intravenously 24 and 48 hours after renal ischemia in ra

22 Mice were given PEGPH20 or vehicle intravenously 24 h before coinjection of (18)F-FAC and (

23 (18)F-flortanidazole was administered intravenously 30 min later, and a second PET/CT scan was

24 0, 15, or 20 mg of doxorubicin per kilogram, intravenously, 48 h beforehand).

25 Cetuximab was given intravenously, 500 mg/m(2) every 2 weeks with regimen on

26 e of nano-SOD/CAT in saline was administered intravenously 6 h post-injury, and the spinal cords were

27 1.8 mg/kg and a placebo form of vincristine intravenously (A+CHP group) or vincristine 1.4 mg/m(2) a

28 his protocol, we describe how to produce and intravenously administer AAVs to adult mice to specifica

29 EMI-137 was intravenously administered (0.13 mg/kg) at a 1-, 2- or 3

30 ed at 40 min and at 2, 4, 24, and 72 h after intravenously administered (38 +/- 9 MBq) (131)I-GMIB-an

31 We show that intravenously administered [(11)C]biotin is quickly dist

32 f-life is an important consideration for any intravenously administered agent in preclinical developm

33 bjective, we determined the accessibility of intravenously administered biodegradable nanoparticles (

34 derlies the acute psychotomimetic effects of intravenously administered delta-9-tetrahydrocannabinol

35 antage of the preferential colocalization of intravenously administered erythrocytes with metastases

36 Moreover, this approach revealed that the intravenously administered GO accumulated predominantly

37 Intravenously administered HN penetrated perihematoma br

38 When regulatory T cells (2 x 106/mouse) were intravenously administered immediately after delayed tPA

39 When intravenously administered in a Wistar rat model, the co

40 Here, we show that an intravenously administered MRI contrast agent consisting

41 Because few intravenously administered MSCs engraft in the myocardiu

42 Intravenously administered MSCs for acute myocardial inf

43 t role in pharmacokinetic and performance of intravenously administered nanomedicines.

44 demonstrated extravasation and retention of intravenously administered nanoparticles specifically at

45 s an opportunity for passive accumulation of intravenously administered nanoparticles through an enha

46 Intravenously administered pHLIP ICG exhibits a multi-ho

47 Intravenously administered procoagulant PL caused clotti

48 Our results indicate that intravenously administered rh proSP-C and Bri2 BRICHOS d

49 Subsequent studies suggested that mice intravenously administered with sMRBC alone may also gen

50 We evaluated the effect of intravenously-administered PLGA nanoparticles on the gut

51 An intravenously administrated near-infrared nanoprobe with

52 Moreover, the intravenously administration of importazole, a specific

53 en received weekly doses of custirsen 640 mg intravenously after three loading doses of 640 mg.

54 scular access site, 2358 received ALPS drugs intravenously and 661 patients by the intraosseous route

55 The first dose of ofatumumab was 300 mg intravenously and all subsequent doses were 2000 mg intr

56 articles (NP-[CPP]) that can be administered intravenously and allow local drug delivery to the disea

57 th bortezomib (1.3 mg/m(2) subcutaneously or intravenously and dexamethasone (20 mg orally).

58 ived a lethal dose of AFB(1) (0.5-1.0 mg/kg) intravenously and hemoperfusion with a CS or Control dev

59 We also administered exogenous oxytocin intravenously and intranasally in a triple dummy, within

60 east cancer were administered (11)C-vorozole intravenously and PET emission data collected between 40

61 oxorubicin 50 mg/m(2) on day 1 of each cycle intravenously and prednisone 100 mg once daily on days 1

62 me of three iv. pulses of methylprednisolone intravenously and the continuation of treatment with im.

63 Patients received nivolumab (240 mg intravenously) and BV (1.8 mg/kg intravenously) every 3

64 mg loading dose, then 420 mg every 3 weeks, intravenously) and trastuzumab (8 mg/kg loading dose, th

65 east cancer were administered (11)C-vorozole intravenously, and PET emission data were collected betw

66 travenously, doxorubicin 50 mg/m(2) on day 1 intravenously, and prednisone 100 mg once daily on days

67 BOMB1 (3 MBq/kg of body weight) was injected intravenously, and safety parameters were assessed.

68 mg once weekly, 300/450 mg every 2 weeks, or intravenously at 20 mg/kg once every 4 weeks up to day 5

69 inacumab subcutaneously at 75/150/250 mg, or intravenously at 5/10/20 mg/kg, monitored up to day 126.

70 3, 6, and 11 after HCT; tacrolimus was given intravenously at a dose of 0.05 mg/kg twice daily (or or

71 Erythropoietin was administered intravenously at a dose of 1000 U per kilogram of body w

72 practices (GMP) conditions, and administered intravenously at either 0.5-1 million Tregs/kg or 3-4.5

73 e approved dosing), both of which were given intravenously at the study site.

74 Participants received vedolizumab (300 mg intravenously) at weeks 0, 2, and 6, and then every 8 we

75 All drugs were given intravenously; brentuximab vedotin and nivolumab were gi

76 ncreased significantly when drugs were given intravenously but not intraosseously, and favored improv

77 platin AUC5 and paclitaxel 175 mg/m(2) given intravenously), by use of a biased coin minimisation pro

78 f norepinephrine, vasopressin, or saline and intravenously challenged with LPS.

79 2) and a placebo form of brentuximab vedotin intravenously (CHOP group) on day 1 of each cycle.

80 ubcutaneously daily or decitabine 20 mg/m(2) intravenously daily for 3 consecutive days on a 28-day c

81 Twenty mg of dexamethasone intravenously daily for 5 days, 10 mg of dexamethasone d

82 assigned to first-line cladribine 0.15 mg/kg intravenously days 1-5 with 8 weekly doses of rituximab

83 al studies have shown that LAmB administered intravenously distributes to tissues frequently infected

84 ceived cyclophosphamide 750 mg/m(2) on day 1 intravenously, doxorubicin 50 mg/m(2) on day 1 intraveno

85 py (two cycles of cisplatin 50 mg/m(2) given intravenously during radiotherapy, followed by four cycl

86 (2), in combination with cytarabine received intravenously every 12 h at either 100 mg/m(2) for 20 do

87 ratio) to receive omadacycline (100 mg given intravenously every 12 hours for two doses, then 100 mg

88 III, or IV) to receive omadacycline (100 mg intravenously every 12 hours for two doses, then 100 mg

89 y every 24 hours) or linezolid (600 mg given intravenously every 12 hours).

90 imab (doses of 2, 6, or 20 mg), administered intravenously every 2 weeks for 12 weeks during hemodial

91 0 mg orally daily plus cetuximab 500 mg/m(2) intravenously every 2 weeks or afatinib alone.

92 gent chemotherapy received avelumab 10 mg/kg intravenously every 2 weeks until human chorionic gonado

93 papillomavirus status, to nivolumab (3 mg/kg intravenously every 2 weeks) or nivolumab (same dose) pl

94 web response system to atezolizumab (840 mg intravenously every 2 weeks) plus cobimetinib (60 mg ora

95 nts were treated with pembrolizumab 10 mg/kg intravenously every 2 weeks.

96 cap at 180 mg) and nivolumab at 3 mg/kg both intravenously every 21 days for 8 cycles.

97 ry 12 hours for two doses, then 100 mg given intravenously every 24 hours) or linezolid (600 mg given

98 ly every 12 hours for two doses, then 100 mg intravenously every 24 hours), or moxifloxacin (400 mg i

99 sly every 24 hours), or moxifloxacin (400 mg intravenously every 24 hours).

100 Trastuzumab was administered intravenously every 3 weeks (8 mg/kg loading dose at fir

101 taxane were treated with T-DM1 at 3.6 mg/kg intravenously every 3 weeks and dose-escalating neratini

102 g/kg intravenously plus pembrolizumab 200 mg intravenously every 3 weeks and six received the recomme

103 0 mg/m(2) and carboplatin area under curve 5 intravenously every 3 weeks for four cycles, followed by

104 receive VRC01 (40 mg/kg) or placebo (saline) intravenously every 3 weeks for up to 24 weeks during an

105 signed (1:1) to receive 200 mg pembrolizumab intravenously every 3 weeks for up to 35 cycles plus 5 m

106 Participants were given pembrolizumab 200 mg intravenously every 3 weeks for up to 35 cycles.

107 orally twice daily plus pembrolizumab 200 mg intravenously every 3 weeks or placebo plus pembrolizuma

108 Patients received 200 mg of pembrolizumab intravenously every 3 weeks until definitive progression

109 t with or without bevacizumab 15 mg/kg given intravenously every 3 weeks until disease progression.

110 nse system) to receive atezolizumab (1200 mg intravenously every 3 weeks) plus chemotherapy (carbopla

111 ay cycle), atezolizumab monotherapy (1200 mg intravenously every 3 weeks), or regorafenib (160 mg ora

112 D) for lenvatinib plus pembrolizumab (200 mg intravenously every 3 weeks).

113 se system to receive cabazitaxel (25 mg/m(2) intravenously every 3 weeks, 10 mg daily prednisone, and

114 25 mg per square meter of body-surface area intravenously every 3 weeks, plus prednisone daily and g

115 getuximab 15 mg/kg plus pembrolizumab 200 mg intravenously every 3 weeks.

116 itaxel 175 mg/m(2), or 75 mg/m(2) docetaxel) intravenously every 3 weeks.

117 ezolizumab 1,200 mg and bevacizumab 15 mg/kg intravenously every 3 weeks.

118 and bevacizumab (10 or 15 mg/kg) were given intravenously every 3 weeks.

119 lizumab (1200 mg) and bevacizumab (15 mg/kg) intravenously every 3 weeks.

120 scheme to receive either BIIB092 or placebo intravenously every 4 weeks for 57 days.

121 0 mg) plus tremelimumab (75 mg) administered intravenously every 4 weeks for up to four doses, follow

122 urvalumab monotherapy (1500 mg) administered intravenously every 4 weeks; durvalumab (1500 mg) plus t

123 50 mg or piperacillin/tazobactam 4 g/500 mg, intravenously every 6 hours for 7-14 days.

124 3 g ceftolozane-tazobactam or 1 g meropenem intravenously every 8 h for 8-14 days.

125 ry 3 weeks] plus nab-paclitaxel [100 mg/m(2) intravenously every week]) or chemotherapy alone for fou

126 r four doses, followed by nivolumab (3 mg/kg intravenously) every 2 weeks; or sunitinib (50 mg orally

127 g/kg intravenously) plus ipilimumab (1 mg/kg intravenously) every 3 weeks for four doses, followed by

128 mab (240 mg intravenously) and BV (1.8 mg/kg intravenously) every 3 weeks until disease progression o

129 All study drugs were given intravenously, every 3 weeks.

130 us placebo and 6 (85.7%) versus 1 (50.0%) on intravenously evinacumab versus placebo reported treatme

131 Treatment was gemcitabine 1,000 mg/m(2) intravenously followed by eribulin 1.4 mg/m(2), both on

132 received 148-444 MBq (4-12mCi) of (18)F-MFBG intravenously followed by serial whole-body imaging at 0

133 Afterward, (18)F-BMS-986192 was administered intravenously, followed by a 60-min dynamic PET scan.

134 roups 1-2) or metformin (100 mg/kg; group 3) intravenously, followed by a single radiotherapy dose of

135 t received therapy with glucocorticosteroids intravenously, followed by intramuscular injections with

136 patients received broad-spectrum antibiotics intravenously for 10 days and orally for the remainder,

137 Patients received decitabine 20 mg/m(2) intravenously for 10 days with oral venetoclax 400 mg da

138 Wistar rats were given omeprazole orally or intravenously for 30 days, and caerulein as a positive c

139 orally twice daily and pembrolizumab 200 mg intravenously for 30 min on day 8 and every 3 weeks for

140 very 12 hours or meropenem 1 g every 8 hours intravenously for 4-14 days.

141 re assigned to receive 20 mg/m(2) decitabine intravenously for 5 or 10 consecutive days as induction

142 For particles injected intravenously for 6 consecutive days to mice with experi

143 ients, antibiotic treatment was administered intravenously for at least 10 days.

144 The vaccine is administered intravenously for maximal efficacy.

145 docetaxel and cabazitaxel, are administered intravenously for the treatment of castration-resistant

146 nding on cisplatin eligibility) administered intravenously for up to six cycles.

147 d to receive monthly tremelimumab (10 mg/kg, intravenously) for six doses, followed by infusions ever

148 with high-dose methylprednisolone (1 g/day, intravenously, for 3-5 days), participants were assigned

149 tudy to evaluate DSTP3086S (0.3 to 2.8 mg/kg intravenously) given once every 3 weeks followed by coho

150 that of extracellular fluid and, when given intravenously, have fewer adverse effects on acid-base b

151 ) relationships that underlie the ability of intravenously (i.v.) administered STING-NPs to induce ST

152 ller than 100 nm or cationic or administered intravenously (i.v.) showed no TAM targeting.

153 Mice were challenged intratracheally (i.t.), intravenously (i.v.), or intraperitoneally (i.p.) with E

154 -(gamma-thio)-triphosphate (ATPgammaS) added intravenously (i.v.).

155 ne of the (89)Zr-labeled antibodies injected intravenously in a peripheral vessel in the left arm.

156 inophil numbers, received 750 mg mepolizumab intravenously in a placebo-controlled double-blind trial

157 either high-dose iron sucrose, administered intravenously in a proactive fashion (400 mg monthly, un

158 40%), or low-dose iron sucrose, administered intravenously in a reactive fashion (0 to 400 mg monthly

159 rol (0.2mmol/kg [0.2ml/kg]) was administered intravenously in all study subjects.

160 ld, patient's metastatic tumor extract given intravenously in dogs, produced significantly increased

161 re this property, three of which were tested intravenously in mice compared to 9.

162 induced transient hypertension when injected intravenously in rodents.

163 The intravenously infused liposomes are able to scavenge the

164 as (HIP rats) and amylin knockout (AKO) rats intravenously infused with aggregated amylin were used f

165 stabilize GANT58, providing a fully aqueous, intravenously injectable formulation based on the polyme

166 o address these limitations, we developed an intravenously-injectable formulation with R848 using the

167 Intravenously injected AAV-Tat or AAV-Exo-Tat mainly inf

168 or alpha (TNFalpha), we found that uptake of intravenously injected antibody to vascular cell adhesio

169 Here, we show that intravenously injected carbon quantum dots, functionaliz

170 (using gut, liver and kidney chips) and for intravenously injected cisplatin (using coupled bone mar

171 g E.G-7 tumor-bearing immune-deficient mice, intravenously injected Cy5.5-CTLs were clearly observed

172 Intravenously injected DAG peptide homes to neurovascula

173 In contrast, intravenously injected engineered MSCs were undetectable

174 We detected prominent binding of intravenously injected F-Dapa in the kidney cortexes of

175 Intravenously injected FAM-labeled UNO (FAM-UNO) homed t

176 burst release of the protein annexin A5 from intravenously injected hollow mesoporous nanoparticles m

177 abeled gold nanoclusters, (64)Cu-AuNCs, were intravenously injected into the mice and imaged by posit

178 Studies with control rats showed that intravenously injected maltitol does not cross the intac

179 MALDI-MSI experiments on spleen tissues from intravenously injected mice indicate that NPSCs loaded w

180 focused ultrasound (FUS), in the presence of intravenously injected microbubbles, to safely and trans

181 Intravenously injected monocytes displayed antitumor act

182 rmore, following biodistribution analysis of intravenously injected nanoparticles in nude mice bearin

183 sed delivery system is reported that enables intravenously injected nerve growth factor (NGF) to ente

184 We show that intravenously injected radioiodinated S1 (I-S1) readily

185 tion time allow for capturing the flow of an intravenously injected tracer through the heart of a mou

186 onjugated with an anti-elastin antibody were intravenously injected twice a week for two weeks.

187 sed from previous studies in which mice were intravenously injected with 0.064-42 kBq of (211)At and

188 Neonate mice intravenously injected with the AAV-BR1-CAG-NEMO vector

189 (18)F-FOL was intravenously injected, followed by imaging with a small

190 ght healthy, malaria-naive participants were intravenously inoculated with blood-stage P. vivax and s

191 l trial involved 2 healthy subjects who were intravenously inoculated with cryopreserved P. malariae-

192 sing small hairpin RNAs; cells were injected intravenously into immune-competent and NOD/SCID mice, a

193 Furthermore, 5% IONP-loaded PFH-NDs injected intravenously into melanoma-bearing mice at a dose of 12

194 In in vivo study, p-XSC was injected intravenously into mice and plasma was collected for LC-

195 lations can be pooled together, administered intravenously into mice as a single pool, and their deli

196 with Alexa750 or (64)Cu-NODAGA and injected intravenously into separate cohorts of nude mice bearing

197 -poly(lactic-co-glycolic) acid, were infused intravenously into wild-type C57BL/6 mice following 2 di

198 h) proSP-C and Bri2 BRICHOS domains injected intravenously into WT mice.

199 mumab subcutaneously (subcutaneous group) or intravenously (intravenous group).

200 be administered once daily either orally or intravenously, is active against pathogens that commonly

201 An intravenously (IV) administered calcimimetic could impro

202 ent antidepressant effects when administered intravenously (IV) at subanesthetic doses (0.5 mg/kg ove

203 andomized 1:1 to receive lefamulin at 150 mg intravenously (IV) every 12 hours or moxifloxacin at 400

204 ith either decitabine (20 mg/m(2), days 1-5, intravenously [IV]) or azacitidine (75 mg/m(2), days 1-7

205 inct clinical signs in C3H/HeN mice infected intravenously, leading to selection of this mouse strain

206 12-month trastuzumab delivered every 3 weeks intravenously (loading dose of 8 mg/kg followed by maint

207 peritoneally (mean = 6,838 HIV copies/ml) or intravenously (mean = 591 HIV copies/ml).

208 ls administered intracerebroventricularly or intravenously mediate antigen-specific protection from t

209 ived two doses of either bimagrumab 30 mg/kg intravenously (n = 33) or placebo (n = 34) (Weeks 0 and

210 In this portion, ublituximab was given intravenously (NHL, 900 mg; CLL, 600 or 900 mg) for 12 c

211 en up to six 28-day cycles were administered intravenously of fludarabine (25 mg/m(2), days 1-3), cyc

212 ived either 10 mg/kg prednisolone (P), or LP intravenously on day 0, 3, and 6, or no additional treat

213 receive four 3-week cycles of CE (75 mg/m(2) intravenously on day 1 and 100 mg/m(2) on days 1 through

214 ived atezolizumab 840 mg or matching placebo intravenously on day 1 and day 15 of every 28-day cycle

215 iltration rate <50 mL/min only) administered intravenously on day 1 and gemcitabine (1000 mg/m(2)) ad

216 received 1200 mg atezolizumab, administered intravenously on day 1 of each 21-day cycle.

217 Trastuzumab duocarmazine was administered intravenously on day 1 of each 3-week cycle.

218 lly (CHP), plus either rituximab 375 mg/m(2) intravenously on day 1 of each cycle (R-CHP) or obinutuz

219 th either atezolizumab (1200 mg administered intravenously on day 1 of each cycle) or placebo.

220 .4 mg/m(2) [to a maximum of 2 mg total dose] intravenously on day 1 of the cycle, and prednisolone 10

221 Pembrolizumab 200 mg was administered intravenously on day 1, and intravenous ramucirumab was

222 ith resectable MCC received nivolumab 240 mg intravenously on days 1 and 15.

223 Daratumumab (8 mg/kg) was administered intravenously on days 1 and 2 of cycle 1 and at 16 mg/kg

224 cers who received sacituzumab govitecan-hziy intravenously on days 1 and 8 of each 21-day cycle until

225 1000 mg/m(2) body surface area, administered intravenously on days 1 and 8 of each cycle), plus eithe

226 and gemcitabine (1000 mg/m(2)) administered intravenously on days 1 and 8; chemotherapy was initiate

227 receive VI (vincristine, 1.5 mg/m(2) per day intravenously on days 1 and 8; irinotecan, 20 mg/m(2) pe

228 1.3 mg/m(2) of bortezomib subcutaneously or intravenously on days 1, 4, 8, and 11 of cycles 1-8, and

229 ), bortezomib (1.3 mg/m(2) subcutaneously or intravenously on days 1, 4, 8, and 11), and dexamethason

230 xate, and bortezomib (bortezomib 1.3 mg/m(2) intravenously on days 1, 4, and 7 after HCT); or tacroli

231 mide-dexamethasone group received isatuximab intravenously on days 1, 8, 15, and 22 in the first 28-d

232 ression with or without elotuzumab (10 mg/kg intravenously on days 1, 8, and 15 for cycles 1-2, on da

233 f each cycle (R-CHP) or obinutuzumab 1000 mg intravenously on days 1, 8, and 15 of cycle 1 and on day

234 -arm study of enfortumab vedotin 1.25 mg/kg (intravenously on days 1, 8, and 15 of every 28-day cycle

235 -paclitaxel 100 mg/m(2) of body surface area intravenously on days 1, 8, and 15 until progression or

236 bumin bound paclitaxel, 100 mg/m2, was given intravenously on days 1, 8, and 15, and repeated every 2

237 cycles of doxorubicin 37.5 mg/m(2) per dose intravenously on days 1-2 every 3 weeks with sequence ad

238 esna) and doxorubicin (37.5 mg/m(2) per dose intravenously on days 1-2) with 45 Gy preoperative radio

239 d six cycles of ifosfamide 3 g/m(2) per dose intravenously on days 1-3 and five cycles of doxorubicin

240 nts received ifosfamide (2.5 g/m(2) per dose intravenously on days 1-3 with mesna) and doxorubicin (3

241 days 1 and 8; irinotecan, 20 mg/m(2) per day intravenously on days 1-5 and 8-12 of a 21-day cycle) in

242 Obinutuzumab 1000 mg was administered intravenously on days 2, 8, and 15 of cycle 1 and day 1

243 g/m(2) on days 1-5 and idarubicin 12 mg/m(2) intravenously on days 2-3 (ie, 5 + 2).

244 latin 25 mg/m(2) and gemcitabine 600 mg/m(2) intravenously on days 3 and 10; treatment for patients i

245 nder the concentration curve 6 mg/mL per min intravenously) on day 1 and paclitaxel (80 mg/m(2) intra

246 n (70 mg/m(2) body surface area administered intravenously) on day 1 of each cycle with either atezol

247 enously) on day 1 and paclitaxel (80 mg/m(2) intravenously) on days 1, 8, and 15 of 21-day cycles com

248 tisotumab vedotin between 0.3 and 2.2 mg/kg intravenously once every 3 weeks in a traditional 3 + 3

249 ezolizumab 1200 mg plus bevacizumab 15 mg/kg intravenously once every 3 weeks or sunitinib 50 mg oral

250 1 to switch maintenance pembrolizumab 200 mg intravenously once every 3 weeks versus placebo for up t

251 e; therefore, 2.0 mg/kg of tisotumab vedotin intravenously once every 3 weeks was established as the

252 once daily orally plus pembrolizumab 200 mg intravenously once every 3 weeks, in 3-week cycles.

253 the SAD and of 83.1% at day 2 with 20 mg/kg intravenously once every 4 weeks (P=0.0003) in the MAD.

254 ntical volume of study drug was administered intravenously once every 4 weeks.

255 Patients received 400 mg spartalizumab intravenously, once every 4 weeks.

256 ib (RB-CHOP group; experimental; 1.3 mg/m(2) intravenously or 1.6 mg/m(2) subcutaneously) on days 1 a

257 PET scans after administration of (11)C-BMP intravenously or by intratracheal aerosolization.

258 o receive pembrolizumab 200 mg every 3 weeks intravenously or investigator's choice of standard doses

259 ne antibiotic agent that can be administered intravenously or orally, reaches high concentrations in

260 ponse system to receive 100 mg/kg opicinumab intravenously or placebo once every 4 weeks (six doses)

261 ously until protocol amendment 1 then either intravenously or subcutaneously on days 1, 4, 8, and 11

262 the curve of 4.5 mg/mL per min administered intravenously) or cisplatin (70 mg/m(2) body surface are

263 ocilizumab (8 mg per kilogram of body weight intravenously) or placebo.

264 otics, or synbiotics; were delivered orally, intravenously, or per rectum; were on biomarkers of syst

265 herapies, and antibodies, which may be dosed intravenously, orally, topically, or by other routes of

266 d photodynamic therapy (4 mg/kg padeliporfin intravenously over 10 min and optical fibres inserted in

267 ne), or oxaliplatin 130 mg/m(2) administered intravenously over 2 h and oral capecitabine 1000 mg/m(2

268 -folinic acid (175 mg flat dose administered intravenously over 2 h) or d,l-folinic acid (350 mg flat

269 -folinic acid (350 mg flat dose administered intravenously over 2 h), and fluorouracil bolus 400 mg/m

270 isted of oxaliplatin 85 mg/m(2) administered intravenously over 2 h, l-folinic acid (175 mg flat dose

271 e status of 0-1) received cemiplimab 3 mg/kg intravenously over 30 min every 2 weeks for up to 96 wee

272 nd instead received melphalan at 200 mg/m(2) intravenously over 30 min on 1 day, followed by ASCT (co

273 The drug was given to participants intravenously over 30 min, and participants were followe

274 fluorouracil bolus 400 mg/m(2) administered intravenously over 5 min, followed by a 46 h infusion of

275 e or 3.3 mg/kg per dose for children <10 kg) intravenously over 6 h on day 1; fluorouracil (600 mg/m(

276 s in part A and were given nivolumab 3 mg/kg intravenously over 60 min on days 1 and 15 of a 28-day c

277 um reduction of 76.9% at day 3 with 10 mg/kg intravenously (P<0.0001) in the SAD and of 83.1% at day

278 reated: three received margetuximab 10 mg/kg intravenously plus pembrolizumab 200 mg intravenously ev

279 igned (1:1) to open-label nivolumab (3 mg/kg intravenously) plus ipilimumab (1 mg/kg intravenously) e

280 When administered intravenously, PpZEV NPs rapidly accumulated in the live

281 Sovateltide (an ETBR agonist) injected intravenously showed better survival and neurological an

282 ses of methotrexate, docetaxel, or cetuximab intravenously (standard-of-care group).

283 ign to receive either azacitidine 75 mg/m(2) intravenously/subcutaneously daily or decitabine 20 mg/m

284 ramagnetic iron oxide nanoparticles (SPIONs) intravenously to detect macrophages.

285 These were administered intravenously to mice bearing low-passage, patient-deriv

286 oid injection to model orthotopic tumors, or intravenously to model hematogenous metastasis, and pros

287 /kg trastuzumab deruxtecan were administered intravenously to patients once every 3 weeks until withd

288 inister deuterated oxytocin intranasally and intravenously to rhesus macaques and measure, with mass

289 days (interquartile range, 14 to 25) in the intravenously treated group and 17 days (interquartile r

290 tcome occurred in 24 patients (12.1%) in the intravenously treated group and in 18 (9.0%) in the oral

291 Bortezomib (1.3 mg/m(2)) was administered intravenously until protocol amendment 1 then either int

292 NSC-derived EV treatment administered either intravenously via retro-orbital vein injection or via in

293 Avelumab 10 mg/kg intravenously was administered every 2 weeks until progr

294 Five healthy volunteers were injected intravenously with 232.4 +/- 1.5 MBq of (18)F-clofarabin

295 r, skin, and lymphoid cancers) were injected intravenously with 9.25 MBq of (86)Y-NM600 and imaged lo

296 Mice were injected intravenously with Cyclo/Dox or the vehicle two hours af

297 Rats treated intravenously with free haloperidol became cataleptic, w

298 C57BL/6 (H-2) (B6) mice were injected intravenously with splenocytes from B6.C.H-2 (H-2k) (bm1

299 Each animal was initially injected intravenously with unlabeled antibody in a peripheral ve

300 ed bendamustine on days 1 and 2 (100 mg/m(2) intravenously) with 40 mg of weekly dexamethasone in 28-